Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE versus MINITEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE versus MINITEC.
HYDROCHLOROTHIAZIDE vs MINITEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
Minitac (misoprostol) is a synthetic prostaglandin E1 analog that inhibits gastric acid secretion and stimulates mucus and bicarbonate production in the stomach, protecting the gastric mucosa. It also induces uterine contractions.
Oral: 25-100 mg daily in 1-2 divided doses. Maximum dose 200 mg/day.
Oral: 10 mg once daily, titrated to blood pressure response; maximum 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 5.6–14.8 hours (mean ~9 hours). In patients with renal impairment (CrCl <30 mL/min), half-life is prolonged up to 24–48 hours, necessitating dose adjustment.
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateHydrochlorothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is approximately 1 hour after subcutaneous administration, reflecting rapid clearance. Clinical context: Requires daily subcutaneous dosing; short half-life supports intermittent PTH receptor stimulation for anabolic effect.
Primarily renal (≥95%) via glomerular filtration and tubular secretion, with approximately 60% of the dose excreted unchanged in urine. Minor biliary/fecal excretion accounts for <5%.
Minitec (teriparatide) is primarily eliminated via hepatic metabolism and renal excretion of metabolites. Approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in bile and feces.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydrochlorothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin."